Clinical assessment of PILA PHARMA’s TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent

Project description

Bringing a novel anti-diabetic drug to the clinic

Fields of science

• medical and health sciences › clinical medicine › endocrinology › diabetes
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

PILA PHARMA AB

Net EU contribution

€ 50 000,00

Address

Vastergatan 1
211 21 Malmo
Sweden

Region

Södra Sverige › Sydsverige › Skåne län

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 21 429,00